Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $741M | $729M | $744M | $851M | $639M | $691M | $678M | $753M | $838M | $825M |
| Revenue growth | — | -1.6% | 2.1% | 14.4% | -25.0% | 8.1% | -1.8% | 11.0% | 11.2% | -1.6% |
| Gross profit | — | — | — | — | — | — | $476M | $517M | $585M | $577M |
| Gross margin | — | — | — | — | — | — | 70.2% | 68.6% | 69.9% | 69.9% |
| Operating income | $153M | $44.0M | $122M | $7.60M | -$232M | -$191M | -$141M | -$257M | -$124M | -$387M |
| Operating margin | 20.7% | 6.0% | 16.4% | 0.9% | -36.3% | -27.6% | -20.7% | -34.2% | -14.7% | -47.0% |
| Net income | $117M | $17.4M | $133M | $4.60M | -$200M | -$27.2M | -$112M | -$263M | -$127M | -$366M |
| Net margin | 15.8% | 2.4% | 17.9% | 0.5% | -31.2% | -3.9% | -16.5% | -35.0% | -15.2% | -44.4% |
| EPS (diluted) | $1.60 | $0.25 | $1.85 | $0.06 | -$2.69 | -$0.35 | -$1.39 | -$3.18 | -$1.41 | -$3.95 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $166M | $106M | $116M | $83.7M | $60.7M | $18.6M | -$106M | -$111M | -$8.70M | $1.80M |
| Capital expenditures | $5.00M | $6.10M | $8.40M | $8.60M | $10.2M | $18.0M | $45.3M | — | — | — |
| Free cash flow | $161M | $100M | $108M | $75.1M | $50.5M | $600K | -$152M | — | — | — |
| Share buybacks | $163M | $31.6M | — | $50.0M | $0.00 | $0.00 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $68.5M | $102M | $111M | $93.2M | $164M | $257M | $56.9M | $132M | $102M | $150M |
| Total assets | $881M | $1.21B | $1.18B | $1.56B | $1.42B | $1.32B | $1.20B | $1.15B | $1.03B | $707M |
| Total liabilities | $132M | $441M | $209M | $474M | $538M | $353M | $313M | $363M | $327M | $339M |
| Long-term debt | — | $99.1M | $9.30M | $234M | $225M | $0.00 | $0.00 | $38.5M | $39.6M | $120M |
| Shareholders' equity | $740M | $768M | $966M | $1.09B | $881M | $968M | $886M | $783M | $701M | $368M |
| Retained earnings | -$73.2M | -$79.2M | $54.1M | $25.6M | -$227M | -$254M | -$366M | -$630M | -$757M | -$1.12B |
| Shares (wtd avg diluted) | 73.4M | 68.8M | 72.0M | 76.0M | 74.3M | 78.0M | 80.6M | 82.8M | 90.6M | 92.6M |
Every figure is extracted from MYRIAD GENETICS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.